07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy; heart failure Myosin heavy chain 7 cardiac muscle-b (MYH7) Mouse studies suggest a cluster of long noncoding RNAs (lncRNAs) encoded by Myh7 loci...
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy Myosin heavy chain 7 cardiac muscle-b (MYH7) Mouse studies suggest RNAi that targets a disease-causing mutation in MYH7 could help prevent hypertrophic cardiomyopathy...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Induced pluripotent stem (iPS) cell-derived models of familial hypertrophic cardiomyopathy (HCM) Patient-derived iPS cell models of familial HCM could help identify new treatments for the...
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
08:00 , Jan 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy Epoxide hydrolase (EPHX2); angiotensin II type 1 receptor (AGTR1) A study in rats suggests that inhibiting...
07:00 , Jun 16, 2008 |  BioCentury  |  Emerging Company Profile

Miragen: The heart of miRNA

Miragen: The heart of miRNA By Aaron Bouchie Senior Writer While currently approved drugs and devices to treat heart failure are palliative, Miragen Therapeutics Inc. is developing drugs against microRNA targets that it believes will...